What is Sertraline Used For? Understanding Its Uses, Benefits, and Side Effects

Sertraline is a widely prescribed medication primarily used to treat a range of mental health conditions. Belonging to the class of selective serotonin reuptake inhibitors (SSRIs), sertraline is recognized for its effectiveness in managing various disorders. This article provides a comprehensive overview of what sertraline is used for, its mechanism of action, administration, potential side effects, and other crucial information for individuals and healthcare professionals.

Indications: What Conditions Does Sertraline Treat?

Sertraline is approved by the Food and Drug Administration (FDA) for the treatment of several mental health disorders. It is a first-line treatment option for:

Major Depressive Disorder (MDD): Sertraline is highly effective in alleviating symptoms of persistent sadness, loss of interest, and feelings of hopelessness associated with major depression. It helps to balance brain chemicals to improve mood and overall emotional well-being.
Obsessive-Compulsive Disorder (OCD): For individuals struggling with OCD, sertraline aids in reducing intrusive thoughts (obsessions) and repetitive behaviors (compulsions). It assists in gaining better control over these distressing symptoms and improving daily functioning.
Panic Disorder: Sertraline is used to manage panic disorder by reducing the frequency and severity of unexpected panic attacks and the associated fear and anxiety about future attacks.
Post-Traumatic Stress Disorder (PTSD): Individuals with PTSD, who often experience symptoms following a traumatic event such as flashbacks, nightmares, and severe anxiety, can benefit from sertraline. It helps to lessen the emotional numbness, hyperarousal, and avoidance behaviors linked to PTSD.
Premenstrual Dysphoric Disorder (PMDD): PMDD is a severe form of premenstrual syndrome (PMS). Sertraline can help manage the mood swings, irritability, depression, and anxiety symptoms that occur in the luteal phase of the menstrual cycle in women with PMDD.
Social Anxiety Disorder (SAD): Also known as social phobia, SAD involves intense fear of social situations. Sertraline helps to reduce anxiety and self-consciousness in social settings, making it easier for individuals to engage in daily interactions.

Beyond its FDA-approved uses, sertraline is also sometimes prescribed off-label for other conditions, including:

Binge Eating Disorder: Sertraline can help reduce the frequency of binge eating episodes and improve control over eating habits.
Body Dysmorphic Disorder: This disorder involves a preoccupation with perceived flaws in physical appearance. Sertraline may help to lessen the distress and anxiety associated with body image concerns.
Bulimia Nervosa: While not a primary treatment, sertraline can be used as part of a comprehensive treatment plan for bulimia nervosa, particularly to address co-occurring depression or anxiety.
Generalized Anxiety Disorder (GAD): Sertraline can be effective in managing the excessive worry and persistent anxiety that characterize GAD.
Premature Ejaculation: Sertraline, due to its effects on serotonin, can sometimes be used to help delay ejaculation in men experiencing premature ejaculation.

How Sertraline Works: Mechanism of Action

Sertraline functions by selectively inhibiting the reuptake of serotonin in the brain. Serotonin is a neurotransmitter, a chemical messenger that plays a crucial role in regulating mood, emotions, sleep, appetite, and various other psychological functions.

After serotonin is released from a nerve ending (presynaptic neuron) and transmits a signal to another nerve ending (postsynaptic neuron), it is normally reabsorbed back into the presynaptic neuron – this process is called reuptake. Sertraline blocks this reuptake process, leading to an increased concentration of serotonin in the synaptic cleft, the space between nerve cells.

By increasing the availability of serotonin, sertraline enhances serotonin neurotransmission. This enhanced serotonergic activity is believed to improve mood, reduce anxiety, and regulate other functions affected by serotonin. While sertraline primarily affects serotonin, it has minimal impact on other neurotransmitters like norepinephrine and dopamine. However, studies suggest sertraline may have more dopaminergic activity compared to other SSRIs, which may contribute to its effectiveness in treating a range of psychiatric conditions.

Administration and Dosage

Sertraline is typically taken orally, once daily, and can be administered in either the morning or evening. If somnolence or drowsiness occurs as a side effect, taking it in the evening may be preferable. Taking sertraline with food may enhance its absorption. It is available in various forms, including oral tablets (25mg, 50mg, 100mg), capsules (150mg, 200mg), and as a liquid solution (20mg/ml).

Adult Dosage Guidelines:

Major Depressive Disorder and OCD: The standard starting dose is 50 mg once daily. Maintenance doses usually range from 50 to 200 mg daily, adjusted based on individual response and tolerance. Dosage adjustments are typically made at weekly intervals.
Premenstrual Dysphoric Disorder (PMDD): Sertraline can be administered continuously (daily) or intermittently (during the luteal phase of the menstrual cycle).
- Continuous Dosing: Start at 50 mg daily, and increase by 50 mg per menstrual cycle if needed, up to a maximum of 150 mg daily.
- Intermittent Dosing: Start at 50 mg daily, increasing to 100 mg daily for the remaining days of the cycle if needed. This intermittent dosing is repeated each cycle.
Panic Disorder, PTSD, and Social Anxiety Disorder: The initial dose is typically lower, starting at 25 mg once daily. The dose is then gradually increased in 50 mg increments weekly, up to a maximum of 200 mg per day.

Special Populations:

Pregnancy: Sertraline is categorized as a Category C medication during pregnancy. It should be used only if the potential benefit justifies the potential risk to the fetus. Consultation with a healthcare provider is crucial when considering sertraline during pregnancy.
Breastfeeding: Sertraline is generally considered a preferred antidepressant for breastfeeding mothers due to its lower transfer into breast milk compared to some other antidepressants.
Hepatic Impairment: Caution is advised for individuals with liver disease. Lower or less frequent doses may be necessary.
Renal Impairment: Dosage adjustments are not typically required for patients with kidney dysfunction.

Withdrawal:

Abruptly stopping sertraline can lead to discontinuation symptoms. These can include nausea, sweating, mood disturbances, dizziness, sensory changes, tremor, anxiety, and sleep problems. It is recommended to gradually reduce the dosage under medical supervision to minimize withdrawal effects.

Adverse Effects and Side Effects

SSRIs like sertraline are generally better tolerated than older antidepressants. However, they can still cause side effects. Common side effects of sertraline may include:

Nausea and diarrhea
Dry mouth (xerostomia)
Increased sweating
Dizziness or lightheadedness
Drowsiness (somnolence) or insomnia
Tremor
Sexual dysfunction, such as decreased libido, erectile dysfunction, or ejaculation disorder
Fatigue
Confusion or hallucinations (less common)

Less Common but Serious Side Effects:

Bleeding Risk: Sertraline can inhibit platelet aggregation, increasing the risk of bleeding, especially when used with other medications that affect blood clotting, like aspirin or NSAIDs.
QT Prolongation: Sertraline can, in rare cases and usually at higher doses, prolong the QT interval on an electrocardiogram (ECG). This effect is generally modest and less pronounced than with some other SSRIs like citalopram.
Serotonin Syndrome: A potentially life-threatening condition that can occur when sertraline is combined with other serotonergic agents. Symptoms include agitation, confusion, muscle rigidity, rapid heart rate, and hyperthermia.
Suicidal Ideation and Behavior: Like other antidepressants, sertraline carries a black box warning about the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults, particularly at the beginning of treatment or when doses are changed.
Hyponatremia: In older adults, sertraline can sometimes cause syndrome of inappropriate antidiuretic hormone secretion (SIADH), leading to hyponatremia (low sodium levels in the blood).
Cardiovascular Malformations in Infants: Studies suggest a slightly increased risk of heart defects in infants born to mothers who used sertraline during the first trimester of pregnancy.
Neonatal Complications: Newborns exposed to sertraline in the third trimester may experience withdrawal symptoms at birth.

Contraindications and Precautions

Sertraline is contraindicated in certain situations:

Hypersensitivity: Individuals with a known allergy to sertraline or any of its components should not take it.
Concomitant Use with MAOIs: Sertraline should not be used with monoamine oxidase inhibitors (MAOIs), including linezolid and methylene blue, due to the risk of serotonin syndrome. There should be a washout period of at least two weeks when switching between sertraline and an MAOI.
Thioridazine or Pimozide: Co-administration with thioridazine or pimozide is contraindicated due to the potential for QT prolongation and cardiac issues.
Disulfiram (Sertraline Solution): The liquid form of sertraline contains alcohol and is contraindicated with disulfiram due to the risk of an alcohol-disulfiram reaction.

Precautions:

Pediatric and Young Adult Use: Increased monitoring for suicidal thoughts and behaviors is needed in this population.
Bipolar Disorder: Sertraline may increase the risk of mania in individuals with bipolar disorder. Screening for bipolar disorder is recommended before starting sertraline.
Bleeding Disorders: Use with caution in patients with bleeding disorders or those taking anticoagulants.
Seizure Disorders: Sertraline should be used cautiously in patients with a history of seizures.
Elderly Patients: Increased risk of hyponatremia and other side effects; lower doses may be needed.
Pregnancy and Breastfeeding: Weigh benefits and risks carefully and discuss with a healthcare provider.

Monitoring and Toxicity

Monitoring:

Regular monitoring is crucial during sertraline treatment. This includes:

Mood and Suicidal Ideation: Monitor for changes in mood, anxiety, and suicidal thoughts, especially during dose changes and at treatment initiation.
Mania Symptoms: Watch for signs of mania, particularly in patients with a family history of bipolar disorder.
Adverse Effects: Monitor for common and serious side effects.
Bleeding: Assess for signs of abnormal bleeding, especially in at-risk patients.
Sodium Levels (in elderly): Regularly check sodium levels in older patients due to the risk of hyponatremia.
QT Interval (if risk factors present): ECG monitoring may be considered in patients with cardiac conditions or risk factors for QT prolongation.

Toxicity and Overdose:

Sertraline overdose is generally considered relatively safe compared to older antidepressants. However, overdose can still be serious and may lead to serotonin syndrome. Symptoms of sertraline toxicity include:

Serotonin syndrome symptoms: agitation, confusion, muscle rigidity, hyperthermia, seizures.
Nausea, vomiting
Tremor, dizziness
Tachycardia

Treatment for sertraline overdose is mainly supportive. In cases of serotonin syndrome, treatment includes:

Discontinuation of sertraline and other serotonergic agents.
Supportive care: managing hyperthermia with cooling measures, administering benzodiazepines for agitation and muscle rigidity, and using antiemetics for nausea.
Serotonin antagonists: In severe cases, medications like cyproheptadine may be used to block serotonin activity.
For severe hyperthermia and muscle rigidity, sedation, neuromuscular paralysis, and intubation may be necessary. Antipyretics are not typically effective for hyperthermia in serotonin syndrome.

Enhancing Healthcare Team Outcomes

Effective use of sertraline requires a collaborative approach among healthcare professionals. Primary care physicians, psychiatrists, nurse practitioners, pharmacists, and nurses all play vital roles in patient care.

Prescribers (Physicians, Nurse Practitioners): Responsible for diagnosis, prescribing, dosage adjustments, and monitoring treatment effectiveness and side effects.
Pharmacists: Review medication regimens, check for drug interactions, counsel patients on medication use and potential side effects, and ensure appropriate dosing.
Nurses: Monitor patients for therapeutic effects, adverse reactions, and adherence to treatment, provide patient education, and communicate concerns to the healthcare team.

Patient education is paramount. Patients should be informed about:

The purpose of sertraline and what conditions it treats.
How to take the medication and dosage instructions.
Potential side effects and what to do if they occur.
The importance of gradual discontinuation and not stopping abruptly.
Signs and symptoms of serotonin syndrome and when to seek immediate medical attention.

By fostering clear communication and shared responsibility among the interprofessional team, and by empowering patients with knowledge about their medication, the healthcare team can optimize the benefits of sertraline therapy while minimizing potential risks and enhancing patient safety and outcomes.

References

Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD006117. [PMC free article: PMC4163971] [PubMed: 20393946]
Fenske JN, Schwenk TL. Obsessive compulsive disorder: diagnosis and management. Am Fam Physician. 2009 Aug 01;80(3):239-45. [PubMed: 19621834]
Hobgood CD, Clayton AH. Sertraline in the treatment of panic disorder. Drugs Today (Barc). 2009 May;45(5):351-61. [PubMed: 19584964]
Buhmann CB, Andersen HS. [Diagnosing and treating post-traumatic stress disorder]. Ugeskr Laeger. 2017 Jun 12;179(24) [PubMed: 28606295]
Aigner M, Treasure J, Kaye W, Kasper S., WFSBP Task Force On Eating Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry. 2011 Sep;12(6):400-43. [PubMed: 21961502]
Kitaichi Y, Inoue T, Nakagawa S, Boku S, Kakuta A, Izumi T, Koyama T. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J Pharmacol. 2010 Nov 25;647(1-3):90-6. [PubMed: 20816814]
Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol. 2014 Jul;29(4):185-96. [PMC free article: PMC4047306] [PubMed: 24424469]
Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A., Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015 Aug;98(2):127-34. [PMC free article: PMC4512908] [PubMed: 25974703]
Preskorn SH, Lane RM. Sertraline 50 mg daily: the optimal dose in the treatment of depression. Int Clin Psychopharmacol. 1995 Sep;10(3):129-41. [PubMed: 8675965]
ACOG Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008 Apr;111(4):1001-20. [PubMed: 18378767]
Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Nov 15, 2024. Sertraline. [PubMed: 30000250]
Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, Huffman JC. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. 2014 May;75(5):e441-9. [PubMed: 24922496]
Duignan KM, Quinn AM, Matson AM. Serotonin syndrome from sertraline monotherapy. Am J Emerg Med. 2020 Aug;38(8):1695.e5-1695.e6. [PubMed: 31837902]
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019 Apr;67(4):674-694. [PubMed: 30693946]
Varela Piñón M, Adán-Manes J. Selective Serotonin Reuptake Inhibitor-Induced Hyponatremia: Clinical Implications and Therapeutic Alternatives. Clin Neuropharmacol. 2017 Jul/Aug;40(4):177-179. [PubMed: 28622213]
Shen ZQ, Gao SY, Li SX, Zhang TN, Liu CX, Lv HC, Zhang Y, Gong TT, Xu X, Ji C, Wu QJ, Li D. Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies. Br J Clin Pharmacol. 2017 Apr;83(4):909-922. [PMC free article: PMC5346877] [PubMed: 27770542]
Sola CL, Bostwick JM, Hart DA, Lineberry TW. Anticipating potential linezolid-SSRI interactions in the general hospital setting: an MAOI in disguise. Mayo Clin Proc. 2006 Mar;81(3):330-4. [PubMed: 16529136]
DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet. 2002;41(15):1247-66. [PubMed: 12452737]
Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE, Kupka RW, Denicoff KD, Nolen WA, Grunze H, Martinez MI, Post RM. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006 Feb;163(2):232-9. [PubMed: 16449476]
Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010 Dec;71(12):1565-75. [PubMed: 21190637]
Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, Mclvor M., Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002 Aug 14;288(6):701-9. [PubMed: 12169073]
O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R., SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010 Aug 24;56(9):692-9. [PMC free article: PMC3663330] [PubMed: 20723799]
Paulzen M, Goecke TW, Stickeler E, Gründer G, Schoretsanitis G. Sertraline in pregnancy – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. J Affect Disord. 2017 Apr 01;212:1-6. [PubMed: 28129551]
Pinheiro E, Bogen DL, Hoxha D, Ciolino JD, Wisner KL. Sertraline and breastfeeding: review and meta-analysis. Arch Womens Ment Health. 2015 Apr;18(2):139-146. [PMC free article: PMC4366287] [PubMed: 25589155]
Wang RZ, Vashistha V, Kaur S, Houchens NW. Serotonin syndrome: Preventing, recognizing, and treating it. Cleve Clin J Med. 2016 Nov;83(11):810-817. [PubMed: 27824534]